KEAP1 and cancer: Nclear factor (erythroid-derived 2)-like 2 (NRF2) and its negative regulator, KEAP1 are frequently mutated in cancer, these mutations drive constitutive NRF2 activation and correlate with poor prognosis (Kerins and Ooi, 2018).